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Abstract
The mesolimbic reward pathway arising from dopaminergic (DA) neurons of the ventral tegmental area (VTA) has been
strongly implicated in reward processing and drug abuse. In rodents, behaviors associated with this projection are
profoundly influenced by an orexinergic input from the lateral hypothalamus to the VTA. Because the existence and
significance of an analogous orexigenic regulatory mechanism acting in the human VTA have been elusive, here we
addressed the possibility that orexinergic neurons provide direct input to DA neurons of the human VTA. Dual-label
immunohistochemistry was used and orexinergic projections to the VTA and to DA neurons of the neighboring substantia
nigra (SN) were analyzed comparatively in adult male humans and rats. Orexin B-immunoreactive (IR) axons apposed to
tyrosine hydroxylase (TH)-IR DA and to non-DA neurons were scarce in the VTA and SN of both species. In the VTA,
15.062.8% of TH-IR perikarya in humans and 3.260.3% in rats received orexin B-IR afferent contacts. On average, 0.2460.05
and 0.0560.005 orexinergic appositions per TH-IR perikaryon were detected in humans and rats, respectively. The majority
(86–88%) of randomly encountered orexinergic contacts targeted the dendritic compartment of DA neurons. Finally, DA
neurons of the SN also received orexinergic innervation in both species. Based on the observation of five times heavier
orexinergic input to TH-IR neurons of the human, compared with the rat, VTA, we propose that orexinergic mechanism
acting in the VTA may play just as important roles in reward processing and drug abuse in humans, as already established
well in rodents.
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Introduction
The neuropeptides orexin A and orexin B (also known as
hypocretin 1 and hypocretin 2) have been implicated in a variety
of behavioral states including feeding [1], sleep and arousal [2],
reward processing and drug abuse [3]. As reviewed recently,
orexinergic signaling modulates many responses to drugs of abuse
and food, such as hyperlocomotor activity and sensitization, drug
withdrawal, self-administration and conditioned place preference
[4].
In rodents, the perikarya of orexin synthesizing neurons are
located in the dorsal medial hypothalamus, perifornical area and
the lateral hypothalamus [1,5–7]. Their axonal projections to the
midbrain ventral tegmental area (VTA) [7–9] have been
implicated in the wide effects of orexins on the mesolimbic reward
pathway [7,9,10]. Both dopaminergic (DA) and GABAergic
neurons of the VTA receive afferent contacts from orexinergic
axons [9–11]. Because synapses are rarely detectable in these
juxtapositions, orexins have been proposed to act mainly via non-
synaptic mechanism upon the A10 DA neurons and GABAergic
interneurons of the VTA [11].
The rodent VTA contains both orexin receptor forms (Ox1R
and Ox2R) [12–14], with particularly high levels of Ox2R [13].
The immunohistochemical detection of Ox1R and Ox2R in DA
[12,14] and non-DA [14] neurons indicates that both cell types of
the VTA represent direct targets for orexinergic actions. In
accordance with these neuroanatomical observations, electrophys-
iological evidence indicates that orexins can activate both DA and
non-DA cells of the VTA via direct postsynaptic mechanisms [14].
Furthermore, ventricular infusion of orexin A induces c-Fos
expression in distinct subsets of VTA DA neurons [15] and orexin
administration into the VTA increases dopamine efflux in the
terminal fields of the mesolimbic reward pathway, the medial
prefrontal cortex [16] and the nucleus accumbens [12]. Acute
application of orexin A into the VTA potentiates N-methyl-D-
aspartate receptors of local neurons and facilitates the plasticity
induced by drugs of abuse [17,18]. Orexinergic mechanisms play
critical roles in the rewarding effect of morphine through the
activation of the mesolimbic DA pathway. Accordingly, morphine-
induced place preference and hyperlocomotion observed in wild-
type mice are absent in the prepro-orexin knockout mice [12].
Orexins appear to exert these behavioral effects mainly via acting
in the VTA because intra-VTA injection of the selective Ox1R
antagonist SB-334867A [1-(2-methylbenzoxazol-6-yl)-3-
[1.5]naphthyridin-4-yl urea] significantly suppresses the mor-
phine-induced place preference in rats [12].
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Although the critical role of a direct orexinergic input to the
VTA in reward processing and drug abuse has been well
established in laboratory rodents [3], the functional significance
of an analogous orexinergic projection in the human has not been
explored. Therefore, in the present study we addressed the issue of
whether orexinergic neurons provide a similar direct input to VTA
DA neurons in the human as reported previously in the rat. To
demonstrate this projection, we first carried out the dual-label
immunohistochemical studies of tissue sections from post-mortem
human midbrain samples and analyzed orexin B-immunoreactive
(IR) neuronal contacts onto DA and non-DA neurons of the VTA.
The surrounding substantia nigra (SN; pars compacta) was also
studied. Notably, the firing of DA neurons at this site of the rat was
unaffected by orexins, whereas orexins excited GABAergic
neurons in the pars reticulata of the SN [19]. To explore
neuroanatomical similarities/differences between the rat and the
human, we next compared quantitatively the incidences of orexin
B-IR axo-somatic contacts onto the VTA and SN DA neurons in
the two species. Finally, the relative contributions of axo-somatic
and axo-dendritic contacts to this communication were deter-
mined quantitatively in each midbrain region and species. Based
on the similar neuroanatomical features of these orexinergic
pathways in the two species, with about five times higher relative
incidences of orexinergic contacts on individual VTA DA neurons
in humans than in rats, we propose that orexin actions in the VTA
may be critically involved in reward processing and drug addiction
in the human, as it has been established well in rodents.
Materials and Methods
Ethics Statement
Human brain tissue samples were obtained at autopsy from the
Forensic Medicine Department of the University of Debrecen,
with the permission of the Regional Committee of Science and
Research Ethics (DEOEC RKEB/IKEB: 3183-2010) and accord-
ing to the Hungarian Law (1997 CLIV and 18/1998/XII.27.
EU¨M Decree/). All personal data were anonymized.
Experiments on rats were carried out in accordance with the
Council Directive of 24 November 1986 of the European
Communities (86/609/EEC) and were reviewed and approved
by the Animal Welfare Committee of the Institute of Experimental
Medicine (No. A5769-01).
Human Subjects
Human VTA and SN tissue samples were used from five male
subjects (Ages: 37, 40, 50, 57 and 59 years). Autopsies were carried
out within 48 h after death (four by suicidal hanging and one by
hypothermia). Known patient histories did not include preexisting
neurological or endocrine disorders and information about
potential drug abuse was not available.
Animals
Five adult (250–350 g body weight) male Wistar rats (Charles
River, Germany) were used for the comparative analysis between
the rat and the human of the orexinergic inputs to midbrain DA
neurons. The rats were housed in a light- (12-h light, 12-h dark
cycle, lights on at 0700 h) and temperature-controlled (2262 C)
environment, with free access to standard food and tap water.
Tissue Preparation for Immunohistochemistry
Preparation of human tissue sections. Human tissue
blocks containing the VTA were dissected out and cut in half in
the midsagittal plane. The blocks were trimmed further so that
coronal sections to be cut could later be accommodated on regular
microscope slides. The blocks were rinsed with running tap water
and then, immersed into 4% formaldehyde in 0.1 M phosphate
buffer saline (PBS; pH 7.4) for 7–14 days at 4uC. The fixed tissues
were infiltrated with 20% sucrose for 5 days at 4uC. The right
halves were placed in freezing molds, surrounded with Jung tissue
freezing medium (Leica Microsystems, Nussloch Gmbh, Germany;
diluted 1:1 with 0.9% sodium chloride solution), snap-frozen on
powdered dry ice, and sectioned coronally at 30 mm with a Leica
SM 2000 R freezing microtome (Leica Microsystems). Sections
14.6–25.2 mm behind the anterior commissure corresponding to
atlas plates 33–41 of the human brain atlas of Mai [20] were
collected and stored permanently in anti-freeze solution (30%
ethylene glycol; 25% glycerol; 0.05 M phosphate buffer; pH 7.4)
at 220uC before use in immunohistochemical studies.
Preparation of rat tissue sections. The rats were anesthe-
tized with a cocktail of ketamine (25 mg/kg), xylavet (5 mg/kg),
and pipolphen (2.5 mg/kg) in saline and then, perfused transcar-
dially with 150 ml fixative solution containing 4% formaldehyde
(Sigma Chemical Co., St. Louis, MO) in 0.1 M PBS (pH 7.4). The
hypothalami were dissected and soaked in 25% sucrose overnight
for cryoprotection. Then, 30-mm-thick free-floating coronal
sections 5.20–5.80 mm posterior to Bregma were cut from the
VTA according to atlas plates 40–43 of Paxinos and Watson [21]
with a freezing microtome and stored in cryoprotectant.
Tissue Pretreatments for Immunohistochemistry
Prior to immunohistochemistry, human and rat sections were
rinsed abundantly in PBS and pretreated with a mixture of 0.5%
H2O2 and 0.2% Triton X-100 for 30 min. In addition, human
sections underwent antigen retrieval using 0.1 M citrate buffer
(pH=6.0) at 80uC for 30 min [22].
Dual-immunoperoxidase Detection of Orexin B-IR Inputs
to Tyrosine Hydroxylase Synthesizing Neurons
Every 24th section of the VTA from each human individual and
every 4th section from each rat was incubated in a goat polyclonal
orexin B antiserum (sc-8071; C-19, 1:50,000; Santa Cruz Biotech
Inc., Santa Cruz, CA) for 48 h at 4uC. This well-characterized
antiserum [23,24] labels orexinergic neurons in various species
and provides no immunostaining of hypothalamic tissues from
orexin deficient mice [24]. Human hypothalamic orexinergic
neurons in our tissue samples showed the same distribution using
this antiserum as described by others using other antibodies [25].
The primary antiserum was reacted with biotinylated secondary
antibodies (donkey biotin-SP-anti-goat IgG; Jackson ImmunoR-
esearch Laboratories, West Grove, PA, USA; 1:500) and the ABC
Elite reagent (Vector, Burlingame, CA; 1:1000) for 60 min each.
The peroxidase signal was visualized with nickel-intensified
diaminobenzidine chromogen and then, post-intensified with
silver-gold [26]. Next, TH neurons were detected with chicken
TH antibodies from AVES laboratories (Aves Laboratories Inc.,
Tigard, OR; #TYH; 1:300, 48 h). The primary antibodies were
reacted with donkey biotin-SP-anti-chicken IgY (Jackson Immu-
noResearch; 1:500; 60 min) and the ABC Elite reagent (1:1000;
60 min) and then, the peroxidase signal was developed using
brown diaminobenzidine. The signal pattern provided by these
antibodies agreed with the known distribution of DA neurons in
the pars compacta of the SN and in other brain regions.
Section Mounting and Coverslipping
The immunostained sections were mounted onto Silanized
microscope slides from Elvanol and dried. Some were stained with
cresyl violet in order to also visualize non-DA cell bodies of the
Orexin Input to VTA DA Neurons
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VTA. Finally, all sections were dehydrated with 95% (5 min),
followed by 100% (265 min) ethanol, cleared with xylene
(265 min) and coverslipped with DPX mounting medium (Sigma,
St. Louis, USA). Representative light microscopic images were
prepared with an AxioCam MRc 5 digital camera mounted on a
Zeiss AxioImager M1 microscope and using the AxioVision 4.6
software (Carl Zeiss, Go¨ttingen, Germany).
Quantitative Light Microscopic Analysis
To address species similarities/differences in the orexin B-IR
input to TH-IR neurons of the VTA and SN, several immuno-
histochemical parameters of these connections were analyzed
quantitatively and data obtained from 5 rats and 5 humans
compared. In each of these comparative studies the counting of
neuronal appositions was carried out using a X63 oil-immersion
objective lense to determine the number of axonal contacts along
the outlines of TH-IR elements, using consistently applied
stringent criteria for contacts [27,28]. In brief, the orexinergic
axon and the TH-IR profile had to be in the same focus plane
without any visible intervening gap and instances of partial overlap
were not considered. The analysis of axosomatic contacts included
1213 DA neurons from the human VTA (28 half sections; 5
individuals), 3860 DA neurons from the human SN (5 sections; 5
individuals), 2729 DA neurons from the rat VTA (5 sections; 5
rats) and 2232 DA neurons from the rat SN (5 sections; 5 rats).
First, the percentages of TH-IR perikarya that received at least
one afferent contact were determined separately in the VTA and
the pars compacta of the SN in both humans and rats. Then, the
average incidence of contacts per TH-IR soma was determined in
each region and species. The above parameters of the two species
were compared with Student’s t-test for independent samples
(Statistica 11 software package; StatSoft Inc., Hungary). Species
differences were considered significant at p,0.05. Finally, the first
randomly encountered one hundred orexin B/TH appositions
were analyzed in one section of each human subject and each rat
to determine the percent distribution of orexin B-IR inputs on the
dendritic (including shafts and dendritic branches) and the somatic
compartments of DA neurons.
Results
Distribution of TH-IR DA Neurons in the VTA and the SN
The light microscopic analysis of immunostained sections from
adult male humans and rats revealed similarities as well as
differences in the distribution of TH-IR DA neurons in the VTA
and the pars compacta of the SN (Figs. 1 and 2).
In humans, DA neurons of the VTA formed a loose cell
population intermingling with TH-immunonegative non-DA
neurons that were only Nissl-stained (Figs. 1B, 2A–E). The DA
neurons showed variable morphology and contained no or only
low amounts of neuromelanin pigment (Figs. 2A–D). The DA
neurons in the pars compacta of the SN, in turn, formed a dense
cell mass and their cytoplasm enclosed numerous golden-brown
neuromelanin granules (Figs. 1C, 2F–H).
In rats, DA cell bodies occurred at high densities both in the
VTA (Figs. 1E, 2I, J) and the SN (Figs. 1F, 2K, L).
Orexin B-IR Innervation of TH-IR Neurons in the VTA and
SN
In humans, scattered orexin B-IR axons, labeled with black
silver-gold-intensified Ni-DAB, were observed in the VTA
(Figs. 2B–E) as well as the SN (Figs. 2G, H). In both regions,
orexinergic axons established axo-dendritic (Figs. 2B–D, G) and,
more sporadically, also axo-somatic (Figs. 2B and H) appositions
onto DA neurons. The majority of TH-IR cell bodies and
dendrites were not surrounded and contacted by orexinergic axons
(not shown). The rarely encountered axo-somatic contacts also
targeted TH-immunonegative non-DA neurons, as evidenced in
Nissl-stained preparations (Fig. 2E).
In rats, orexin B-IR axons provided even more scarce inputs to
DA neurons as in humans, both in the VTA (Figs. 2I, J) and the
SN (Figs. 2K, L).
Results of Quantitative Comparisons between Species
Quantitative comparisons between species revealed the follow-
ing similarities/differences in the innervation patterns of DA
neurons.
In the VTA, the incidences of TH-IR cell bodies receiving
orexin B-IR contacts were low in the human (15.062.8%) and
even lower (3.260.3%) in the rat. Similarly in the SN, only
8.761.6% of DA somata in the human and 4.060.9% in the rat
received orexin B-IR appositions (Fig. 3). Species differences were
statistically significant by t-test (N= 5, t = 4.17, p = 0.003 for the
VTA and N=5, t = 2.6, p = 0.031 for the SN).
In the VTA, the mean frequency of axosomatic appositions
(contacts/TH-IR perikaryon) was 0.2460.05 in the human and
only 0.0560.005 in the rat. In the SN, the mean incidence of these
axosomatic contacts was 0.1860.03 in the human and 0.0760.01
Figure 1. Immunohistochemical detection of dopaminergic
neurons in the VTA and the SN of the human and the rat.
Representative low-power images of immunostained sections from an
adult male human (A) and rat (D) illustrate the distribution of tyrosine
hydroxylase (TH)-immunoreactive (IR) dopaminergic neurons in the
ventral tegmental area (VTA) and pars compacta of the substantia nigra
(SN). Medium-power images (insets B, C, E and F) reveal that the pars
compacta of the SN contains densely-packed dopaminergic neurons
(arrows) in both species. In contrast, while dopaminergic neurons are
distributed loosely in the human VTA (arrows in B), they exhibit a
relatively high regional cell density in the VTA of the rat (arrows in E).
Cresyl violet staining in A–C visualizes non-dopaminergic perikarya.
Scale bar = 200 mm in A, D and 66 mm in B, C, E, F.
doi:10.1371/journal.pone.0083029.g001
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in the rat (Fig. 4). Species differences were statistically significant
by t-test (N= 5, t = 3.52, p = 0.008 for the VTA and N=5,
t = 2.87, p = 0.021 for the SN). Overall, in the VTA as well as the
SN, both the incidence of TH-IR cell bodies receiving orexin B-IR
input and the number of orexinergic appositions per TH-IR
perikaryon were significantly higher in humans than in rats.
Finally, humans and rats showed a similarity in the preferential
targeting of the orexinergic inputs to the dendritic vs. the somatic
compartment of DA neurons at both anatomical sites. 86.662.7%
of the orexin B-IR apposition in the human and 87.061.3% in the
rat VTA were directed to the dendritic compartment of DA
neurons (Fig. 5). Similarly in the SN, 88.462.9% from the first 100
randomly encountered orexin B/TH appositions in each human
subject and 86.262.1% in each rat targeted dendrites.
Discussion
This immunohistochemical study provides evidence for direct
orexinergic inputs to TH-IR DA neurons of the human VTA and
SN. The patterns of orexinergic innervation in the human were
similar to the analoguous orexinergic pathways in the rat, except
for three aspects. First, the regional density of TH-IR cell bodies
detectable in the VTA of the human was much lower than in the
rat, resulting in lower numbers of DA cells analyzed in the human
VTA. Second, the percentages of DA neurons (both in the VTA
and the SN) innervated by orexinergic axons were several times
higher in the human, compared with the rat. Third, the incidence
of orexinergic inputs to individual DA neurons was also several
times higher in the human compared with the rat. In both species
and both regions, the majority (86–88%) of orexinergic inputs
targeted the dendritic compartment of DA neurons.
Orexins originally described in 1998 by two independent groups
[1,6] are synthesized in the dorsal medial hypothalamus,
perifornical area and the lateral hypothalamus [1,5–7,25] and
send extensive projections to the central nervous system [7–9].
The wide effects of orexins on the mesolimbic reward pathway
of laboratory rodents have been established in a number of
behavior tests. At least some drugs of abuse can act on orexinergic
neurons directly while eliciting these behavioral responses.
Orexinergic neurons contain m opioid receptor [32] which may
underlie the mechanism whereby morphine withdrawal by
naloxone- or naltrexone following chronic morphine treatment,
induces cAMP response element (CRE)-mediated transcription in
CRE-LacZ reporter mice as well as c-Fos and orexin expression in
orexinergic neurons of the lateral hypothalamus [32]. The somatic
responses to withdrawal are attenuated in the presence of the
Ox1R antagonist SB-334867 [33] and in orexin knock-out mice
[32]. In self-administration paradigms, orexin receptor antagonists
are capable of inhibiting the self-administration of nicotine [34]
and alcohol [35,36]. Orexinergic neurons are also involved in the
reinstatement of extinguished responses to drugs of abuse.
Accordingly, stimulation of lateral hypothalamic orexinergic
neurons, or microinjection of orexin A into the VTA, can
reinstate an extinguished morphine place preference [30].
Furthermore, intracerebroventricular administration of orexin A
is capable of reinstating extinguished responses in animals trained
to self-administer cocaine and food reinforcers [37] and similarly,
extinguished cocaine seeking behavior can be reinstated by intra-
VTA administration of orexin A [38]. Stimuli linked to ethanol
availability can also increase Fos expression in orexin neurons, as
shown in a reinstatement model of relapse [39]. Reinstatement of
extinguished alcohol self-administration by alcohol-associated cues
is absent in rats treated with SB-334867 [35]. The above and other
regulatory effects of orexinergic neurotransmission on the meso-
limbic reward pathway have been summarized in a number of
recent review articles [4,29,30,40,41].
Figure 2. Orexin B-immunoreactive inputs to dopaminergic
and non-dopaminergic neurons in the human and rat VTA and
SN. Images of histological samples from an adult male human (A–H)
and rat (I–L) illustrate orexin B (black) and tyrosine hydroxylase (TH;
brown) immunoreactivities visualized with the silver-gold intensified
nickel-diaminobenzidine and diaminobenzidine chromogens, respec-
tively, in the ventral tegmental area (VTA; A–E, I, J) and the pars
compacta of the substantia nigra (SN; F–H, K, L). Cresyl violet was
applied in A–H to also reveal non-dopaminergic perikarya in human
midbrain sections. Arrows in high power photomicrographs point to
the sporadically encountered neuronal appositions between orexin B-
immunoreactive (IR) axons and TH-IR (B–D, G, H, J, L) or TH-
immunonegative (E) perikarya and dendrites. Dopaminergic neurons of
the human VTA (A–E) form a loose cell mass in which TH-IR
dopaminergic and Nissl-labeled non-dopaminergic neurons intermin-
gle. Orexin B-IR appositions can only be observed on a relatively small
subset of the dopaminergic cell bodies (B) and dendrites (B, D). Framed
regions in C are shown in high-power micrographs D and E and
illustrate orexinergic contacts on a TH-IR dendrite (D) and a TH-
immunonegative Nissl-stained perikaryon (E), respectively. The pars
compacta of the human SN exhibits a high density of dopaminergic cell
bodies which contain dark brown neuromelanin (nm) granules (F–H).
High-power images illustrate the infrequent apposition of orexin B-IR
axons to the dendrites (G) and perikarya (H) of a small subset of TH-IR
dopaminergic neurons. The VTA of the rat (I) exhibits a higher density
of dopaminergic neurons, compared with the human VTA (A).
Orexinergic contacts (J) on these neurons are rare. Similarly to the
human, dopaminergic neurons of the rat form a compact cell
population in the SN (K) and receive orexin B-immunoreactive inputs
infrequently (L). Comparison of the above innervation patterns in the
two species provides quantitative evidence for significantly heavier
input frequencies in the human (Figs. 3 and 4), whereas Fig. 5 illustrates
that the vast majority of orexinergic inputs target the dendritic
compartment of dopaminergic neurons in both regions of both species.
p, TH-IR perikarya; d, TH-IR dendrites; nm, dopaminergic cell bodies
containing high levels of neuromelanin pigment. Scale bar = 10 mm in
D, E, G, H, 30 mm in B, C, J, L and 130 mm in A, F, I, K.
doi:10.1371/journal.pone.0083029.g002
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The relevance of animal data to the putative orexinergic
regulation of the human reward circuitry has been unclear. In the
present study we first established that a direct orexinergic
projection to VTA DA neurons also exists in the human. Next,
we compared several quantitative aspects of this communication
pathway between the human and the rat species. First, we found
that the input was not abundant in either the human or the rat and
only low subsets of VTA DA perikarya were contacted by
orexinergic axons; the percentage of DA neurons innervated by
orexin B-IR fibers was five times higher in the human
(15.062.8%) than in the rat (3.260.3%). Second, the mean
incidence of axosomatic contacts was also found to be low in both
species, but again, about five times higher in the human
(0.2460.05) than in the rat (0.0560.005). Finally, in both species
about 87% of the orexinergic contacts were observed on the
dendritic compartment of VTA DA neurons. Based on the
observations that i) the percentage of VTA DA neurons receiving
orexinergic innervation ii) and the number of orexinergic contacts
on individual VTA DA neurons were five times higher in the
human than in the rat, we propose that orexinergic mechanisms
acting in the human VTA play critical roles in reward processing
Figure 3. Percentages of dopaminergic somata receiving orexinergic innervation in the VTA and the SN. Bar graph illustrates the low
percentages of tyrosine hydroxylase-immunoreactive dopaminergic neuronal cell bodies that receive innervation from orexin B-immunoreactive
axons in the ventral tegmental area (VTA) and substantia nigra (SN) of adult male humans and rats. Note that while the axo-somatic innervation is
quite sparse in both species, the percentage of dopaminergic cell bodies receiving orexinergic input is 5-times higher in the human compared with
the rat VTA and 2.2-times higher in the human compared with the rat SN. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0083029.g003
Figure 4. Mean incidences of orexin B-immunoreactive afferent contacts onto individual dopaminergic cell bodies. The mean
incidences of orexin B-immunoreactive afferent contacts onto the cell bodies of dopaminergic neurons in the ventral tegmental area (VTA) and the
substantia nigra (SN) are low both in adult male humans and rats. Individual dopaminergic cell bodies receive 5-times more orexinergic appositions in
the human compared with the rat VTA and 2.6-times more appositions in the human compared with the rat SN. *p,0.05; **p,0.01.
doi:10.1371/journal.pone.0083029.g004
Orexin Input to VTA DA Neurons
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and drug abuse, as already established well in laboratory rodents
[4,29–31].
While our immunohistochemical data suggest that, in humans,
orexins influence VTA DA and non-DA neurons at the somato-
dendritic level, additional orexin-dopamine interactions may also
take place at the level of DA terminals of VTA origin. Previous
studies on rats revealed that some of the important mesolimbic
terminal fields, including the central amygdala, the medial
prefrontal cortex and the nucleus accumbens, receive abundant
DA as well as orexinergic inputs [9]. Orexin receptor activation is
excitatory in the amygdale [42] and the medial prefrontal cortex
[43] and inhibitory [44] or excitatory [45] in the nucleus
accumbens in different studies. It is important to recognize that
orexinergic projections from the lateral hypothalamus may also
regulate the DA systems of the VTA and the SN indirectly. Recent
evidence suggests that GABAergic neurons of the tail of the VTA/
rostromedial tegmental nucleus play a critically important role as a
major GABAergic brake for VTA and SN DA systems [46].
Whether or not these GABAergic interneurons serve as additional
targets for the descending orexinergic projections, requires
clarification.
Coronal sections containing the VTA in our study also included
the pars compacta of the SN. DA cells in the human SN tend to
accumulate more neuromelanin pigment, in comparison with DA
neurons of the VTA [47] which latter contain higher levels of
vesicular monoamine transporter-2 for the vesicular packaging of
dopamine and DOPA [48]. The analysis of orexinergic inputs to
DA neurons of this region has shown that SN DA neurons of rats
as well as humans receive direct innervation from hypothalamic
orexinergic neurons. Although this input is quite sporadic, it is
important to note that a similarly sparse innervation is capable of
inducing robust behavioral effects in the rodent VTA
[4,29,30,40,41]. Functional evidence also exists that orexins can
act in the SN to influence important motor functions. Orexin A
can significantly increase the time spent moving when injected into
the pars compacta of the rat SN and D1 receptor activation is
needed for the orexin A-induced increase in ambulation [49].
Interestingly however, DA neurons of the SN do not respond to
orexins with excitation [19], unlike either VTA DA neurons
[14,36] or GABAergic interneurons in the pars reticulata of the
SN [19].
In summary, in the present study we provide anatomical
evidence for direct orexin B-IR inputs to subsets of DA and non-
DA neurons of the human VTA and SN. Comparative analyses of
sections from male rats and humans revealed that the innervation
of VTA DA neurons is about three-five-times heavier in humans
than in rats. We conclude that the role of orexin actions in the
human VTA may be at least as important in reward processing
and drug abuse, as established previously in rats.
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